Skip to content
View in the app

A better way to browse. Learn more.

BariatricPal

A full-screen app on your home screen with push notifications, badges and more.

To install this app on iOS and iPadOS
  1. Tap the Share icon in Safari
  2. Scroll the menu and tap Add to Home Screen.
  3. Tap Add in the top-right corner.
To install this app on Android
  1. Tap the 3-dot menu (⋮) in the top-right corner of the browser.
  2. Tap Add to Home screen or Install app.
  3. Confirm by tapping Install.

Join BariatricPal free

  • Ask your own questions
  • Reply and follow topics
  • Message other members
  • No cost, no spam

Apollo Endosurgery, Inc. Announces the Presentation of ORBERA™ Intragastric Balloon US Pivotal Trial Results at Digestive Disease Week 2015 Conferenc

AUSTIN, Texas--Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, today announced the presentation of results from the ORBERA™ Pivotal Trial at this year’s Digestive Disease Week (DDW) conference. The study showed that ORBERA™ Intragastric Balloon users lost significantly more weight than the control group, leading to significant improvement in weight related quality of life and improved eating behaviors.

“At the completion of the study, it was clear that the ORBERA™ Intragastric Balloon produced significant weight loss and quality of life benefits, when compared to the study’s control group,” said Dr. Barham Abu Dayyeh, Gastroenterologist and Advanced Endoscopist at The Mayo Clinic. “The results of this study prove that ORBERA™ can be an outstanding tool to aide weight loss and support sustainable, healthy habits, even after it has been removed.”

In the US pivotal ORBERA™ clinical trial, a multicenter, prospective, randomized, non-blinded comparative study, obese patients with a BMI between 30 and 40 were randomized to treatment or control in a 1:1 ratio. The treatment group underwent placement of the ORBERA™ balloon followed by removal after 6 months. They concurrently participated in a 12-month behavioral modification program. The control group participated in the 12-month behavioral modification program alone. For patients in the treatment group, the device was removed at month 6, with regular office visits continuing through 1 year.

A total of 125 patients were randomized to the treatment group and 130 patients were randomized to the control group. More than three-fourths (78.4 percent, 98/125) of the treatment group and 71.5 percent (93/130) of the control group completed the full study at Week 52.

Detailed findings from the trial include:

  • At month six, the ORBERA™ group achieved a mean of 40 percent Excess Weight Loss (EWL), with 72 percent of ORBERA™-treated patients achieving at least 25 percent EWL
  • Mean Total Body Weight Loss (TBWL) at six months was 10.54 percent for the treatment group compared to 4.71 percent TBWL for the control group.
  • The ORBERA™ group lost over twice as much weight as the control group at six months.
  • The ORBERA™ group also lost significantly more weight than the control group over the course of the study, and was able to maintain significant weight loss through month 12, six months after removal of the device.

The ORBERA™ Pivotal Trial results were presented at the AGA/ASGE Joint Presidential Plenary Sessions by Dr. Barham Abu Dayyeh. The DDW session was titled “A Randomized, Multi-Center Study to Evaluate the Safety and Effectiveness of an Intragastric Balloon as an Adjunct to a Behavioral Modification Program, in Comparison with a Behavioral Modification Program Alone in the Weight Management of Obese Subjects.” Apollo Endosurgery is exhibiting at booth 1905.

  • Replies 2
  • Views 2.3k
  • Created
  • Last Reply

Featured Replies

Interesting. Balloons have been in use in the UK for many years (don't know if the same sort, but the same principle). I wouid be very interested to see follow up studies say a year later. I would be surprised if the weight stayed off. I know it had at the 12 month mark in this study, so 6 months after balloon removal. I wonder if it stayed off longer!

  • Author

Interesting. Balloons have been in use in the UK for many years (don't know if the same sort, but the same principle). I wouid be very interested to see follow up studies say a year later. I would be surprised if the weight stayed off. I know it had at the 12 month mark in this study, so 6 months after balloon removal. I wonder if it stayed off longer!

These aren't the same Balloons that have been in use in Europe but in theory they work the same way. Balloons are a great tool for surgeons to use on patients that are affected by super morbid obesity. It allows them to shed a decent amount of weight prior to undergoing weight loss surgery. Balloon's could also be a great training tools for those that are overweight but have a low BMI and don't qualify for surgery. I am also VERY curious how many patients keep the weight off once the Balloon device is removed. Guess only time will tell.

Archived

This topic is now archived and is closed to further replies.

Account

Navigation

Search

Search

Configure browser push notifications

Chrome (Android)
  1. Tap the lock icon next to the address bar.
  2. Tap Permissions → Notifications.
  3. Adjust your preference.
Chrome (Desktop)
  1. Click the padlock icon in the address bar.
  2. Select Site settings.
  3. Find Notifications and adjust your preference.